Lectin-like oxidised low-density lipoprotein receptor 1 (LOX-1) is a transmembrane glycoprotein expressed on endothelial cells, macrophages and vascular smooth muscle cells. By binding and ...

Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...

"There is a dose-dependent, log-linear association between absolute LDL cholesterol and cardiovascular risk, and this association is independent of other cardiovascular risk factors and is consistent ...

Cholesterol lowering with a strategy using the short interfering RNA agent, inclisiran, earlier in the treatment pathway led to significantly better long-term low-density lipoprotein (LDL) reduction ...

A new breakthrough could change how high cholesterol is treated, offering a powerful alternative to traditional drugs. Researchers have developed tiny DNA-based molecules that shut down PCSK9—a key ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Please provide your email address to receive an email when new articles are posted on . CETP inhibition may help high-risk patients reach their LDL goals and reduce risk for atherosclerotic CVD events ...

Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...